Have questions for our experts or want more information?
Contact Us Today
Webinar Overview: Streamline Oncology Study Planning
Developing cancer therapeutics demands significant time and resources. Preparing an IND alone can take three to six years, and moving toward market approval requires an even greater investment. Choosing the wrong model early on can lead to delays, higher costs, and weakened confidence in your downstream decisions. That’s why it’s critical to select models that align with your therapeutic modality, mechanism of action, tumor type, and stage of development.
In this webinar, we’ll include a demonstration of the newly updated Charles River Cancer Model Database and show how integrated data streamlines and strengthens your model selection. The session will cover:
- Choosing the ideal rodent host strain
- Interpreting genomic and phenotypic datasets to refine model choice
- Comparing PDX, CDX, cell line, and syngeneic models for scientific fit
- Uncovering insights to strengthen early oncology planning and reduce uncertainty
Webinar Presenter
Julia Schueler, DVM, PhD
Therapeutic Area Lead Oncology
Charles River